RU2002135626A - NEW FORM (R) -N- [5METHYL-8- (4-METHYLPIPERAZIN-1-IL) -1,2,3,4-TETRAHYDRO-2-NAPTIL] -4-MOR FOLINOBENZAMIDE - Google Patents

NEW FORM (R) -N- [5METHYL-8- (4-METHYLPIPERAZIN-1-IL) -1,2,3,4-TETRAHYDRO-2-NAPTIL] -4-MOR FOLINOBENZAMIDE

Info

Publication number
RU2002135626A
RU2002135626A RU2002135626/04A RU2002135626A RU2002135626A RU 2002135626 A RU2002135626 A RU 2002135626A RU 2002135626/04 A RU2002135626/04 A RU 2002135626/04A RU 2002135626 A RU2002135626 A RU 2002135626A RU 2002135626 A RU2002135626 A RU 2002135626A
Authority
RU
Russia
Prior art keywords
methylpiperazin
tetrahydro
morpholinobenzamide
monohydrobromide
naphthyl
Prior art date
Application number
RU2002135626/04A
Other languages
Russian (ru)
Inventor
Пер-Олов БЕРГСТРЁМ (SE)
Пер-Олов БЕРГСТРЁМ
Мартин ХЕДБЕРГ (SE)
Мартин ХЕДБЕРГ
Мона ЛИНДСТРЁМ (SE)
Мона ЛИНДСТРЁМ
Эрика СТОХЛЕ (SE)
Эрика СТОХЛЕ
Original Assignee
Астразенека Аб (Se)
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб (Se), Астразенека Аб filed Critical Астразенека Аб (Se)
Publication of RU2002135626A publication Critical patent/RU2002135626A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Claims (4)

1. Форма А моногидробромида (R)-N-[5-метил-8-(4-метилпиперазин-1-ил)-1,2,3,4-тетрагидро-2-нафтил]-4-морфолинобензамида.1. Form A of monohydrobromide (R) -N- [5-methyl-8- (4-methylpiperazin-1-yl) -1,2,3,4-tetrahydro-2-naphthyl] -4-morpholinobenzamide. 2. Форма А моногидробромида (R)-N-[5-метил-8-(4-метилпиперазин-1-ил)-1,2,3,4-тетрагидро-2-нафтил]-4-морфолинобензамида по п.1, которая представляет собой по существу кристаллографически чистую Форму А моногидробромида (R)-N-[5-метил-8-(4-метилпиперазин-1-ил)-1,2,3,4-тетрагидро-2-нафтил]-4-морфолинобензамида.2. Form A of the monohydrobromide (R) -N- [5-methyl-8- (4-methylpiperazin-1-yl) -1,2,3,4-tetrahydro-2-naphthyl] -4-morpholinobenzamide according to claim 1 which is a substantially crystallographically pure Form A of (R) -N- [5-methyl-8- (4-methylpiperazin-1-yl) -1,2,3,4-tetrahydro-2-naphthyl] -4 monohydrobromide morpholinobenzamide. 3. Форма А моногидробромида (R)-N-[5-метил-8-(4-метилпиперазин-1-ил)-1,2,3,4-тетрагидро-2-нафтил]-4-морфолинобензамида по п.2, содержащая не более 10% любой другой кристаллической формы моногидробромида (R)-N-[5-метил-8-(4-метилпиперазин-1-ил)-1,2,3,4-тетрагидро-2-нафтил]-4-морфолинобензамида.3. Form A of the monohydrobromide (R) -N- [5-methyl-8- (4-methylpiperazin-1-yl) -1,2,3,4-tetrahydro-2-naphthyl] -4-morpholinobenzamide according to claim 2 containing not more than 10% of any other crystalline form of monohydrobromide (R) -N- [5-methyl-8- (4-methylpiperazin-1-yl) -1,2,3,4-tetrahydro-2-naphthyl] -4 morpholinobenzamide. 4. Форма А моногидробромида (R)-N-[5-метил-8-(4-метилпиперазин-1-ил)-1,2,3,4-тетрагидро-2-нафтил]-4-морфолинобензамида по п.1, дающая картину дифракции рентгеновских лучей на порошке, демонстрирующую по существу следующие d-значения и относительные интенсивности.4. Form A of the monohydrobromide (R) -N- [5-methyl-8- (4-methylpiperazin-1-yl) -1,2,3,4-tetrahydro-2-naphthyl] -4-morpholinobenzamide according to claim 1 giving a X-ray powder diffraction pattern showing essentially the following d-values and relative intensities.
RU2002135626/04A 2000-07-20 2001-07-17 NEW FORM (R) -N- [5METHYL-8- (4-METHYLPIPERAZIN-1-IL) -1,2,3,4-TETRAHYDRO-2-NAPTIL] -4-MOR FOLINOBENZAMIDE RU2002135626A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002729-2 2000-07-20
SE0002729A SE0002729D0 (en) 2000-07-20 2000-07-20 Novel compound form

Publications (1)

Publication Number Publication Date
RU2002135626A true RU2002135626A (en) 2004-07-27

Family

ID=20280557

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002135626/04A RU2002135626A (en) 2000-07-20 2001-07-17 NEW FORM (R) -N- [5METHYL-8- (4-METHYLPIPERAZIN-1-IL) -1,2,3,4-TETRAHYDRO-2-NAPTIL] -4-MOR FOLINOBENZAMIDE

Country Status (24)

Country Link
US (1) US6706710B2 (en)
EP (1) EP1305303A1 (en)
JP (1) JP2004504390A (en)
KR (1) KR20030015398A (en)
CN (1) CN1443178A (en)
AR (1) AR029588A1 (en)
AU (2) AU7287201A (en)
BR (1) BR0112619A (en)
CA (1) CA2415046A1 (en)
CZ (1) CZ2003140A3 (en)
EE (1) EE200300028A (en)
HU (1) HUP0301116A3 (en)
IL (1) IL153836A0 (en)
IS (1) IS6679A (en)
MX (1) MXPA03000439A (en)
NO (1) NO20030220L (en)
NZ (1) NZ523528A (en)
PL (1) PL365112A1 (en)
RU (1) RU2002135626A (en)
SE (1) SE0002729D0 (en)
SK (1) SK732003A3 (en)
UA (1) UA72333C2 (en)
WO (1) WO2002008212A1 (en)
ZA (1) ZA200300129B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201001889A1 (en) 2008-06-20 2011-08-30 Астразенека Аб DERIVATIVES OF DIBENZOTHIAZEPINE AND THEIR APPLICATION
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (en) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co Pyridazinone Compounds and Their Use as DAAO Inhibitors
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
CA2914263C (en) 2013-06-21 2021-05-18 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (en) 2020-03-04 2021-09-16 武田薬品工業株式会社 Oral solid preparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (en) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9900190D0 (en) * 1999-01-22 1999-01-22 Astra Ab New compounds
SE9702799D0 (en) * 1997-07-25 1997-07-25 Astra Ab New compounds

Also Published As

Publication number Publication date
AU7287201A (en) 2002-02-05
NO20030220L (en) 2003-03-14
IL153836A0 (en) 2003-07-31
MXPA03000439A (en) 2003-06-24
AU2001272872B2 (en) 2005-08-25
SE0002729D0 (en) 2000-07-20
ZA200300129B (en) 2004-06-25
WO2002008212A1 (en) 2002-01-31
IS6679A (en) 2003-01-14
NZ523528A (en) 2004-09-24
CN1443178A (en) 2003-09-17
UA72333C2 (en) 2005-02-15
AR029588A1 (en) 2003-07-02
US6706710B2 (en) 2004-03-16
SK732003A3 (en) 2003-08-05
BR0112619A (en) 2003-07-29
PL365112A1 (en) 2004-12-27
JP2004504390A (en) 2004-02-12
US20030166653A1 (en) 2003-09-04
NO20030220D0 (en) 2003-01-16
KR20030015398A (en) 2003-02-20
HUP0301116A3 (en) 2006-03-28
CA2415046A1 (en) 2002-01-31
EE200300028A (en) 2004-10-15
CZ2003140A3 (en) 2003-06-18
HUP0301116A2 (en) 2003-08-28
EP1305303A1 (en) 2003-05-02

Similar Documents

Publication Publication Date Title
RU2002135626A (en) NEW FORM (R) -N- [5METHYL-8- (4-METHYLPIPERAZIN-1-IL) -1,2,3,4-TETRAHYDRO-2-NAPTIL] -4-MOR FOLINOBENZAMIDE
CY2306B1 (en) Sulfonamide, preparation and use thereof as medicine and intermediate.
RU96119782A (en) DERIVATIVES 7-AMINO-1H-INDOLA
SE9802974D0 (en) New crystalline forms
ATE79622T1 (en) 1,4-DIAZEPINS.
HRP20030853B1 (en) Crystalline form of omeprazole
JP2001354766A5 (en)
DE69912992D1 (en) FAUJASITE TYPE ZEOLITHIC MATERIAL
DE69111607D1 (en) PURE CRYSTALLINE SHAPED BY RIFAPENTIN.
RU2002124524A (en) DERIVATIVES OF N-DEACETHILTIOCOLCHICINE AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
DE58901409D1 (en) Hydroxypropafenonglyceride.
DE69940922D1 (en) Polymorph Form B of 3- (cyclopropylmethoxy) -4-i4- (methylsulfonyl) phenyl-5,5-dimethyl-5H-furan-2-one
USD262066S (en) Combined dental pick, dental floss holder and dental aid container
ES2081608T3 (en) ZEOLITE KL CONTAINING IRON.
JPS57156467A (en) 2,4-disubstituted-6-quinazolinesulfonamide derivative
MA22435A1 (en) A NEW VARIETY OF HYBRID CLASS ROSE, WITH LARGE FLOWERS, GENERALLY UNIFLORE (VARIETY: PEKCOURUI)
MA22434A1 (en) A NEW VARIETY OF HYBRID CLASS ROSE, WITH LARGE FLOWERS, GENERALLY UNIFLORE (VARIETY: PEKCOUGRAINE)
MA22427A1 (en) A NEW VARIETY OF HYBRID CLASS ROSE, WITH LARGE FLOWERS, GENERALLY UNIFLORE (VARIETY: PEKCENKATORZ)
MA22423A1 (en) A NEW VARIETY OF HYBRID CLASS ROSE, WITH LARGE FLOWERS, GENERALLY UNIFLORE (VARIETY: PEKCOULUNE)
MA22422A1 (en) A NEW VARIETY OF HYBRID CLASS ROSE, WITH LARGE FLOWERS, GENERALLY UNIFLORE (VARIETY: PEKCOULISTE)
MA22421A1 (en) A NEW VARIETY OF HYBRID CLASS ROSE, WITH LARGE FLOWERS, GENERALLY UNIFLORE (VARIETY: PEKCOUPINK)
MA22419A1 (en) A NEW VARIETY OF HYBRID CLASS ROSE, WITH LARGE FLOWERS, GENERALLY UNIFLORE (VARIETY: PEKCOUJACHERE)
JP2000100236A5 (en)
MA22426A1 (en) A NEW VARIETY OF ROSE OF THE HYBRID TEA CLASS, WITH LARGE FLOWERS, GENERALLY UNIFLORE (VARIETY: PEKCOUGELOSIA)
MA22425A1 (en) A NEW VARIETY OF ROSE OF THE HYBRID CLASS OF TEA, WITH LARGE FLOWERS, GENERALLY UNIFLORE (VARIETY: PEKWHINA)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20050714